Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial

Joel Gallant, Graeme Moyle, Juan Berenguer, Peter Shalit, Huyen Cao, Ya-Pei Liu, Joel Myers, Lisa Rosenblatt, Lingfeng Yang, Javier Szwarcberg, Joel Gallant, Graeme Moyle, Juan Berenguer, Peter Shalit, Huyen Cao, Ya-Pei Liu, Joel Myers, Lisa Rosenblatt, Lingfeng Yang, Javier Szwarcberg

Abstract

Objectives: Cobicistat (COBI) enhances atazanavir (ATV) pharmacokinetic parameters similarly to ritonavir (RTV) in both healthy volunteers and HIV-infected adults. Primary efficacy and safety outcomes of this Phase 3, international, randomized, double-blind, double-dummy, active- controlled trial in HIV-1-infected treatment-naïve adults (GS-US-216-0114/NCT01108510) demonstrated that ATV+COBI was non-inferior to ATV+RTV, each in combination with emtricitabine/ tenofovir disoproxil fumarate (FTC/TDF), at Weeks 48 and 144, with high rates of virologic success for both regimens (85.2% and 87.4%, respectively, at Week 48; and 72.1% and 74.1% at Week 144), and with comparable safety and tolerability. Here, we describe virologic response and treatment discontinuation by a wider range of subgroups than previously presented.

Methods: Subgroup analyses by baseline CD4 count (≤200, 201-350, >350 cells/mm3), baseline HIV-1 RNA level (≤100,000, >100,000 copies/mL), race, sex, and age (<40, ≥40 years) evaluated ATV+COBI versus ATV+RTV univariate odds ratios (ORs) for virologic success (viral load <50 copies/mL, intention-to-treat US Food and Drug Administration Snapshot algorithm) and discontinuation due to adverse events (AEs) at Weeks 48 and 144. Of 692 patients randomized, 344 received ATV+COBI and 348 ATV+RTV.

Results: ATV+COBI versus ATV+RTV ORs for virologic success did not significantly differ by regimen overall at Weeks 48 and 144 (OR 0.90; 95% confidence interval [CI]: 0.64, 1.26) or within subgroups, except in females, for whom ATV+COBI was favored at Week 144 (OR 2.36; 95% CI: 1.02, 5.47). However, there were more discontinuations due to withdrawal of consent and pregnancies in females receiving ATV+RTV versus ATV+COBI. ORs for discontinuation due to AEs did not significantly differ by regimen overall at Weeks 48 and 144 (OR 0.98; 95% CI: 0.61, 1.58) or within subgroups.

Conclusion: These findings indicate that both ATV+COBI and ATV+RTV, each with FTC/TDF, are effective and well-tolerated treatment options across a wide demographic range of HIV-infected patients.

Keywords: Atazanavir; HIV-1; cobicistat; pharmacokinetic; ritonavir; subgroup analysis; virologic.

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Figures

Fig. (1)
Fig. (1)
Patient disposition at randomization, at Week 48, and at Week 144.
Fig. (2)
Fig. (2)
Proportions and univariate odds ratios (95% CI) for virologic success.

References

    1. Bristol-Myers Squibb Company Prescribing information for REYATAZ® (atazanavir). [updated: September 2015; cited: 21 September 2016]; Available from:
    1. Deeks E.D. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014;74(2):195–206. doi: 10.1007/s40265-013-0160-x.
    1. Gallant J.E., Koenig E., Andrade-Villanueva J., Chetchotisakd P., DeJesus E., Antunes F., Arastéh K., Moyle G., Rizzardini G., Fehr J., Liu Y., Zhong L., Callebaut C., Szwarcberg J., Rhee M.S., Cheng A.K. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J. Infect. Dis. 2013;208(1):32–39. doi: 10.1093/infdis/jit122.
    1. Gallant J.E., Koenig E., Andrade-Villanueva J.F., Chetchotisakd P., DeJesus E., Antunes F., Arastéh K., Rizzardini G., Fehr J., Liu H.C., Abram M.E., Cao H., Szwarcberg J. Brief report: Cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results. J. Acquir. Immune Defic. Syndr. 2015;69(3):338–340. doi: 10.1097/QAI.0000000000000598.
    1. US Food and Drug Administration US Food and Drug Administration. New Drug Application approval for EVOTAZ® (atazanavir and cobicistat) tablet, 300 mg and 150 mg. [updated: 29 January 2015; cited: 14 March 2016]; Available from:
    1. Bristol-Myers Squibb Company Prescribing information for EVOTAZ® (atazanavir and cobicistat). [updated: May 2015; cited: 23 November 2015]; Available from:
    1. Tashima K., Crofoot G., Tomaka F.L., Kakuda T.N., Brochot A., Van de Casteele T., Opsomer M., Garner W., Margot N., Custodio J.M., Fordyce M.W., Szwarcberg J. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res. Ther. 2014;11:39. doi: 10.1186/1742-6405-11-39.
    1. Mills A., Crofoot G., Jr, McDonald C., Shalit P., Flamm J.A., Gathe J., Jr, Scribner A., Shamblaw D., Saag M., Cao H., Martin H., Das M., Thomas A., Liu H.C., Yan M., Callebaut C., Custodio J., Cheng A., McCallister S. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: A randomized phase 2 study. J. Acquir. Immune Defic. Syndr. 2015;69(4):439–445. doi: 10.1097/QAI.0000000000000618.
    1. Casado J.L., Perez-Elías M.J., Antela A., Sabido R., Martí-Belda P., Dronda F., Blazquez J., Quereda C. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS. 1998;12(11):F131–F135. doi: 10.1097/00002030-199811000-00005.
    1. Grabar S., Pradier C., Le Corfec E., Lancar R., Allavena C., Bentata M., Berlureau P., Dupont C., Fabbro-Peray P., Poizot-Martin I., Costagliola D. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000;14(2):141–149. doi: 10.1097/00002030-200001280-00009.
    1. Molina J.M., Andrade-Villanueva J., Echevarria J., Chetchotisakd P., Corral J., David N., Moyle G., Mancini M., Percival L., Yang R., Thiry A., McGrath D., CASTLE Study Team Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646–655. doi: 10.1016/S0140-6736(08)61081-8.
    1. Molina J.M., Andrade-Villanueva J., Echevarria J., Chetchotisakd P., Corral J., David N., Moyle G., Mancini M., Percival L., Yang R., Wirtz V., Lataillade M., Absalon J., McGrath D., CASTLE Study Team Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J. Acquir. Immune Defic. Syndr. 2010;53(3):323–332. doi: 10.1097/QAI.0b013e3181c990bf.
    1. Ortiz R., Dejesus E., Khanlou H., Voronin E., van Lunzen J., Andrade-Villanueva J., Fourie J., De Meyer S., De Pauw M., Lefebvre E., Vangeneugden T., Spinosa-Guzman S. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389–1397. doi: 10.1097/QAD.0b013e32830285fb.
    1. Mills A.M., Nelson M., Jayaweera D., Ruxrungtham K., Cassetti I., Girard P.M., Workman C., Dierynck I., Sekar V., Abeele C.V., Lavreys L. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679–1688. doi: 10.1097/QAD.0b013e32832d7350.
    1. Orkin C., DeJesus E., Khanlou H., Stoehr A., Supparatpinyo K., Lathouwers E., Lefebvre E., Opsomer M., Van de Casteele T., Tomaka F. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Med. 2013;14(1):49–59. doi: 10.1111/j.1468-1293.2012.01060.x.
    1. Clotet B., Feinberg J., van Lunzen J., Khuong-Josses M.A., Antinori A., Dumitru I., Pokrovskiy V., Fehr J., Ortiz R., Saag M., Harris J., Brennan C., Fujiwara T., Min S., ING114915 Study Team Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222–2231. doi: 10.1016/S0140-6736(14)60084-2.
    1. Molina J.M., Clotet B., van Lunzen J., Lazzarin A., Cavassini M., Henry K., Kulagin V., Givens N., de Oliveira C.F., Brennan C., FLAMINGO study team Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127–e136. doi: 10.1016/S2352-3018(15)00027-2.
    1. Lennox J.L., Landovitz R.J., Ribaudo H.J., Ofotokun I., Na L.H., Godfrey C., Kuritzkes D.R., Sagar M., Brown T.T., Cohn S.E., McComsey G.A., Aweeka F., Fichtenbaum C.J., Presti R.M., Koletar S.L., Haas D.W., Patterson K.B., Benson C.A., Baugh B.P., Leavitt R.Y., Rooney J.F., Seekins D., Currier J.S., ACTG A5257 Team Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann. Intern. Med. 2014;161(7):461–471. doi: 10.7326/M14-1084.
    1. Boffito M., Jackson A., Amara A., Back D., Khoo S., Higgs C., Seymour N., Gazzard B., Moyle G. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation. Antimicrob. Agents Chemother. 2011;55(9):4218–4223. doi: 10.1128/AAC.01747-10.
    1. Mathias A., Liu H.C., Warren D., Sekar V., Kearney B.P. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus RTV [Abstract 28]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, 7–9 April 2010, Sorrento, Italy. Available from: 2010.
    1. Kakuda T.N., Opsomer M., Timmers M., Iterbeke K., Van De Casteele T., Hillewaert V., Petrovic R., Hoetelmans R.M. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J. Clin. Pharmacol. 2014;54(8):949–957. doi: 10.1002/jcph.290.
    1. Kakuda T.N., Brochot A., Tomaka F.L., Vangeneugden T., Van De Casteele T., Hoetelmans R.M. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. J. Antimicrob. Chemother. 2014;69(10):2591–2605. doi: 10.1093/jac/dku193.
    1. Clumeck N., Molina J-M., Henry K., et al. Elvitegravir/ cobicistat/emtricitabine/tenofovir df (stb) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir df at week 144 in treatment-naive HIV-1 infected patients. EACS Online Library. Oct 18, 2013; 39247. . [cited: 22 September 2016]; Available from: 2013.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever